92 related articles for article (PubMed ID: 21348807)
1. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
Poordad F; Theodore D; Sullivan J; Grotzinger K
J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
[TBL] [Abstract][Full Text] [Related]
2. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Lidgren M; Hollander A; Weiland O; Jönsson B
Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
[TBL] [Abstract][Full Text] [Related]
3. Doing battle with HCV.
Fimmel CJ
Am J Gastroenterol; 2000 Mar; 95(3):582-3. PubMed ID: 10710043
[No Abstract] [Full Text] [Related]
4. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
[TBL] [Abstract][Full Text] [Related]
5. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
[TBL] [Abstract][Full Text] [Related]
6. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
8. [Thrombocytopenia in HCV infection. Natural interferon as an alternative therapy].
Krzowska-Firych J; Modrzewska R; Kiciak SG
Przegl Epidemiol; 2007; 61(4):771-6. PubMed ID: 18572510
[TBL] [Abstract][Full Text] [Related]
9. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
10. Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease.
Brown RS
Aliment Pharmacol Ther; 2007 Nov; 26 Suppl 1():41-8. PubMed ID: 17958518
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye.
Giannini EG; Savarino V
J Viral Hepat; 2011 Jan; 18(1):8-10. PubMed ID: 20796207
[TBL] [Abstract][Full Text] [Related]
12. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
13. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
[TBL] [Abstract][Full Text] [Related]
14. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Bressler BL; Guindi M; Tomlinson G; Heathcote J
Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
16. Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
Korr M
R I Med J (2013); 2014 Jul; 97(7):29-30. PubMed ID: 24983018
[No Abstract] [Full Text] [Related]
17. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis C virus infection in patients with end-stage renal disease.
Liu CH; Kao JH
J Gastroenterol Hepatol; 2011 Feb; 26(2):228-39. PubMed ID: 21261711
[TBL] [Abstract][Full Text] [Related]
19. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
20. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
